Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Mirati Therapeutics stock price, quote, forecast and news

MRTX
US60468T1051
A1W1XV

Price

58.70
Today +/-
+0
Today %
+0 %
P

Mirati Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Mirati Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Mirati Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Mirati Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Mirati Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Mirati Therapeutics Stock Price History

DateMirati Therapeutics Price
1/23/202458.70 undefined
1/22/202458.70 undefined

Mirati Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Mirati Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Mirati Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Mirati Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Mirati Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Mirati Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Mirati Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Mirati Therapeutics’s growth potential.

Mirati Therapeutics Revenue, EBIT and net profit per share

DateMirati Therapeutics RevenueMirati Therapeutics EBITMirati Therapeutics Net Income
2030e2.79 B undefined1.32 B undefined1.22 B undefined
2029e1.44 B undefined1.08 B undefined414.29 M undefined
2028e1.03 B undefined87.82 M undefined140.78 M undefined
2027e736.43 M undefined-194.2 M undefined-146.81 M undefined
2026e505.03 M undefined-420.6 M undefined-413.76 M undefined
2025e329.19 M undefined-729.49 M undefined-544.87 M undefined
2024e182.56 M undefined-550.04 M undefined-652.86 M undefined
2023e62.95 M undefined-536.5 M undefined-794.51 M undefined
202212.44 M undefined-759.59 M undefined-740.87 M undefined
202172.09 M undefined-573.18 M undefined-581.78 M undefined
202013.4 M undefined-369.36 M undefined-357.94 M undefined
20193.34 M undefined-222.1 M undefined-213.26 M undefined
201812.93 M undefined-102.63 M undefined-98.42 M undefined
20170 undefined-71.54 M undefined-70.43 M undefined
20160 undefined-83.78 M undefined-83.12 M undefined
20150 undefined-64.71 M undefined-64.54 M undefined
20140 undefined-38.77 M undefined-43.7 M undefined
20130 undefined-30.97 M undefined-52.91 M undefined
20120 undefined-20.5 M undefined-20.29 M undefined
20113.13 M undefined-10.18 M undefined-9.84 M undefined
20102.32 M undefined-14.2 M undefined-14.22 M undefined
20092.65 M undefined-20.23 M undefined-20.68 M undefined
200827.64 M undefined-11.73 M undefined-8.36 M undefined
200714.44 M undefined-20.72 M undefined-20.52 M undefined
200614.13 M undefined-3.26 M undefined-6.62 M undefined
20055.52 M undefined-12.82 M undefined-12.63 M undefined
20046.51 M undefined-8.46 M undefined-8.46 M undefined
20037.15 M undefined-2.94 M undefined-3.91 M undefined

Mirati Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023e2024e2025e2026e2027e2028e2029e2030e
0.0100.010.010.010.010.010.030000000000.0100.010.070.010.060.180.330.510.741.031.442.79
--42.8675.00-14.29-16.67180.00-92.86-92.59-50.00--------75.00333.33453.85-83.33416.67193.5580.7753.5045.7439.4039.8694.56
---------150.00133.33----------91.67--------
0000000003400000000001100000000
0-0-0-0.01-0.01-0-0.02-0.01-0.02-0.01-0.01-0.02-0.03-0.04-0.06-0.08-0.07-0.1-0.22-0.37-0.57-0.76-0.54-0.55-0.73-0.42-0.190.091.081.32
--100.00-28.57-133.33-240.00-21.43-142.86-40.74-1,000.00-700.00-333.33-------850.00-7,400.00-2,838.46-795.83-6,325.00-864.52-302.20-221.58-83.17-26.368.4875.1247.21
0-0-0-0.01-0.01-0.01-0.02-0.01-0.02-0.01-0.01-0.02-0.05-0.04-0.06-0.08-0.07-0.1-0.21-0.36-0.58-0.74-0.79-0.65-0.54-0.41-0.150.140.411.22
---25.00166.6750.00-50.00233.33-60.00150.00-30.00-35.71122.22160.00-17.3148.8429.69-15.6640.00117.3567.6162.7527.377.30-17.88-16.56-24.08-64.65-195.89195.71194.44
0.30.330.330.380.430.570.710.730.750.814.946.7611.0613.4816.919.7925.2930.937.4744.9951.8856.2300000000
------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Mirati Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Mirati Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
200220032004200520062007200820092010201120122013201420152016201720182019202020212022
                                         
0.020.020.030.020.060.060.030.020.010.030.040.060.030.120.060.150.220.421.391.491.08
0.60.50.40.52.24.20.20.40.4000000000000.9
2.63.2111.62.21.71.11.11.400000000002.8
0000003.50.30000000000003
0.40.50.60.70.30.60.60.4-0.30.61.923.22.92.74.73.17.811.314.118.4
0.020.030.040.020.060.070.040.020.010.030.040.060.030.130.060.160.230.421.41.511.11
2.73.23.13.63.13.11.81.10.40.20.30.30.50.60.60.50.52.447.753.553.7
00000.30.30.30.40.10.10000000015.68.224.5
000000000000000000000
11.51.61.71.820000000000000014.9
000000000000000000000
00000000.60.70.30.100.323.311.35.49.2190.6
3.74.74.75.35.25.42.12.11.20.60.40.30.82.63.91.51.87.872.580.793.7
0.030.030.040.030.070.070.040.020.010.030.040.060.030.130.060.160.230.431.471.591.2
                                         
35.341.761.86485.2118.597.1113.3119.6142.9000000000.10.10.1
00000.010.010.010.010.020.020.170.210.260.420.430.590.751.142.483.13.45
-12.7-19.6-30.2-44.4-50.8-81.5-75.7-110-130.8-137.5-140.5-198.4-242.1-306.6-389.8-460.6-559-772.3-1,130.2-1,712-2,452.9
00000-0.10.30009.59.59.59.69.59.59.59.99.89.1-3.7
000000000000000000000
0.020.020.040.020.040.050.030.0100.030.030.030.030.120.050.140.20.381.361.41
1.322.33.34.48.57.65.50.50.81.81.31.72.16.34.38.516.418.135.238.9
000000003.733.63.93.77.78.79.317.232.453.4108.5120.6
0.62.31.40.63.94.30.60.70.90033.400000.40.1000
600600200000000000000000000
000000000000000000000
2.54.93.93.98.312.88.26.25.13.85.438.65.49.81513.626.148.971.5143.7159.5
000000000000000000000
000000000000000000000
0.73.11.82.116.415.12.72.81.8000000.10.30.7143.948.146.7
0.73.11.82.116.415.12.72.81.8000000.10.30.7143.948.146.7
3.285.7624.727.910.996.93.85.438.65.49.815.113.926.849.9115.4191.8206.2
0.030.030.040.030.070.070.040.020.010.030.040.060.030.130.060.160.230.431.481.591.2
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Mirati Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Mirati Therapeutics's financial health and stability.

Assets

Mirati Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Mirati Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Mirati Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Mirati Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
0-4-3-8-12-6-20-8-20-14-9-20-52-43-64-83-70-98-213-357-581-740
0001111100000000000012
0000000000000000000000
-3140016-3-1400010-134013131665-10
000100200004261920211330107155239363
0000000000000000000000
0000000000000000000000
-3-21-5-1011-20-21-18-15-11-16-29-32-50-68-64-70-147-271-388-570
-1-10-1-10-100000000000-1-4-9-4
-50-2-911-35523242-180-2924-5038-8-145-176-139-588225
-31-1-812-34623242-180-2924-5038-8-145-174-135-579230
0000000000000000000000
0000000000000000000000
0.01000.0200.020.020000.030.020.0500.1400.160.140.341.250.510.17
0.01000.0200.020.02000.010.030.020.0500.1400.160.140.341.250.510.17
000-200-1006-240000001000
0000000000000000000000
000000227-628-4-742-2785-7514839-472-177
-4.71-4.290.52-6.65-12.3310.84-22.13-21.25-18.82-15.28-11.8-16.88-29.66-33.14-51.04-68.22-64.79-70.22-149.28-275.9-398.6-575.42
0000000000000000000000

Mirati Therapeutics stock margins

The Mirati Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Mirati Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Mirati Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Mirati Therapeutics's sales revenue. A higher gross margin percentage indicates that the Mirati Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Mirati Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Mirati Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Mirati Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Mirati Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Mirati Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Mirati Therapeutics Margin History

Mirati Therapeutics Gross marginMirati Therapeutics Profit marginMirati Therapeutics EBIT marginMirati Therapeutics Profit margin
2030e95.18 %47.21 %43.67 %
2029e95.18 %75.12 %28.87 %
2028e95.18 %8.56 %13.72 %
2027e95.18 %-26.37 %-19.93 %
2026e95.18 %-83.28 %-81.93 %
2025e95.18 %-221.6 %-165.52 %
2024e95.18 %-301.29 %-357.61 %
2023e95.18 %-852.25 %-1,262.11 %
202295.18 %-6,106.03 %-5,955.55 %
202195.18 %-795.09 %-807.02 %
202095.18 %-2,756.42 %-2,671.19 %
201995.18 %-6,649.7 %-6,385.03 %
201895.18 %-793.74 %-761.18 %
201795.18 %0 %0 %
201695.18 %0 %0 %
201595.18 %0 %0 %
201495.18 %0 %0 %
201395.18 %0 %0 %
201295.18 %0 %0 %
2011128.43 %-325.24 %-314.38 %
2010137.93 %-612.07 %-612.93 %
200995.18 %-763.4 %-780.38 %
200895.18 %-42.44 %-30.25 %
200795.18 %-143.49 %-142.11 %
200695.18 %-23.07 %-46.85 %
200595.18 %-232.25 %-228.8 %
200495.18 %-129.95 %-129.95 %
200395.18 %-41.12 %-54.69 %

Mirati Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Mirati Therapeutics earnings per share therefore indicates how much revenue Mirati Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Mirati Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Mirati Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Mirati Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Mirati Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Mirati Therapeutics Revenue, EBIT and net profit per share

DateMirati Therapeutics Sales per ShareMirati Therapeutics EBIT per shareMirati Therapeutics Earnings per Share
2030e39.8 undefined0 undefined17.38 undefined
2029e20.46 undefined0 undefined5.91 undefined
2028e14.63 undefined0 undefined2.01 undefined
2027e10.5 undefined0 undefined-2.09 undefined
2026e7.2 undefined0 undefined-5.9 undefined
2025e4.69 undefined0 undefined-7.77 undefined
2024e2.6 undefined0 undefined-9.31 undefined
2023e0.9 undefined0 undefined-11.33 undefined
20220.22 undefined-13.51 undefined-13.18 undefined
20211.39 undefined-11.05 undefined-11.21 undefined
20200.3 undefined-8.21 undefined-7.96 undefined
20190.09 undefined-5.93 undefined-5.69 undefined
20180.42 undefined-3.32 undefined-3.19 undefined
20170 undefined-2.83 undefined-2.78 undefined
20160 undefined-4.23 undefined-4.2 undefined
20150 undefined-3.83 undefined-3.82 undefined
20140 undefined-2.88 undefined-3.24 undefined
20130 undefined-2.8 undefined-4.78 undefined
20120 undefined-3.03 undefined-3 undefined
20110.63 undefined-2.06 undefined-1.99 undefined
20102.86 undefined-17.53 undefined-17.56 undefined
20093.53 undefined-26.97 undefined-27.57 undefined
200837.86 undefined-16.07 undefined-11.45 undefined
200720.34 undefined-29.18 undefined-28.9 undefined
200624.79 undefined-5.72 undefined-11.61 undefined
200512.84 undefined-29.81 undefined-29.37 undefined
200417.13 undefined-22.26 undefined-22.26 undefined
200321.67 undefined-8.91 undefined-11.85 undefined

Mirati Therapeutics business model

Mirati Therapeutics Inc is a biotechnology company based in San Diego, California, that focuses on the discovery and development of personalized therapies for cancer. The company was founded in 1995 and originally focused on developing drugs for the treatment of inflammatory diseases. However, in 2012, the company changed its strategy and began to focus on cancer therapies. Mirati Therapeutics' business model is based on the discovery and development of drugs for cancer patients with specific genetic mutations or abnormalities. The company utilizes new insights in cancer genomics to develop targeted therapeutic approaches tailored to the specific needs of cancer patients. The company operates in three different business areas: preclinical research, clinical development, and commercial products. In the preclinical research area, the company focuses on investigating new target candidates and identifying potential drugs for the treatment of cancer. Clinical development involves conducting clinical trials to evaluate the effectiveness and safety of drugs in relation to specific types of cancer. The company also works on marketing and selling commercial products that are already approved on the market and used for the treatment of cancer. One of Mirati Therapeutics' products is the drug Adagrasib, a treatment for patients with advanced non-small cell lung cancer (NSCLC) and specific genetic mutations. Adagrasib aims to inhibit the activity of KRAS, an oncogene that is overexpressed in many types of cancer. The company also has other drugs in the pipeline that are still in preclinical or clinical development. Mirati Therapeutics has partnerships with other companies in the biotech and pharmaceutical industries to advance the discovery and development of new therapies. In 2020, the company announced a strategic collaboration with the pharmaceutical company Amgen to combine Amgen's KRAS inhibitor portfolio with Mirati's and receive milestone payments. The company works closely with the FDA and other regulatory authorities to obtain approval for new drugs and demonstrate the safety and efficacy of its products. The company has made significant progress in the development of personalized cancer therapies in recent years and hopes to be able to help even more patients in the future. In summary, Mirati Therapeutics Inc is an innovative biotechnology company that focuses on the discovery and development of personalized cancer therapies. The company collaborates closely with other industry partners to develop and bring new drugs to the market. Mirati Therapeutics strives to improve the lives of cancer patients and hopes to offer even more innovative therapies in the future. Mirati Therapeutics is one of the most popular companies on Eulerpool.com.

Mirati Therapeutics SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Mirati Therapeutics Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Mirati Therapeutics Revenue by Segment

Segmente2022
License and collaboration revenues11.72 M USD
Product revenue, net713,000 USD

Mirati Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Mirati Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Mirati Therapeutics shares outstanding

The number of shares was Mirati Therapeutics in 2023 — This indicates how many shares 56.23 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Mirati Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Mirati Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Mirati Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Mirati Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Mirati Therapeutics.

Mirati Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2023-2.9 -2.49  (14 %)2023 Q3
6/30/2023-3.23 -3.04  (6.02 %)2023 Q2
3/31/2023-3.62 -3.18  (12.21 %)2023 Q1
12/31/2022-3.62 -3.51  (3.16 %)2022 Q4
9/30/2022-3.55 -3.09  (12.84 %)2022 Q3
6/30/2022-3.56 -3.18  (10.56 %)2022 Q2
3/31/2022-3.56 -3.4  (4.4 %)2022 Q1
12/31/2021-3.06 -3.72  (-21.42 %)2021 Q4
9/30/2021-2.94 -1.55  (47.35 %)2021 Q3
6/30/2021-2.45 -3.23  (-31.9 %)2021 Q2
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Mirati Therapeutics stock

Eulerpool World ESG Rating (EESG©)

75/ 100

🌱 Environment

86

👫 Social

99

🏛️ Governance

41

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees24.4
Share of Asian management—
Percentage of Hispanic/Latino employees6.7
Hispano/Latino Management share—
Percentage of Black employees4.6
Black Management Share—
Percentage of white employees60.3
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Mirati Therapeutics list of shareholders

%
Name
Stocks
Change
Date
8.19444 % EcoR1 Capital, LLC5,748,3995,748,3999/22/2023
7.91954 % Avoro Capital Advisors LLC5,555,55506/30/2023
7.08454 % The Vanguard Group, Inc.4,969,806-72,2956/30/2023
6.37632 % RTW Investments L.P.4,472,985829,8716/30/2023
5.67071 % Armistice Capital LLC3,978,000286,0006/30/2023
4.83017 % Wellington Management Company, LLP3,388,365692,2736/30/2023
4.56371 % Boxer Capital, L.L.C.3,201,440010/8/2023
4.47037 % Aviva Holdings Ltd.3,135,966010/8/2023
3.96845 % Morgan Stanley & Co. LLC2,783,8691,023,0586/30/2023
3.68031 % State Street Global Advisors (US)2,581,739271,9196/30/2023
1
2
3
4
5
...
10

Mirati Therapeutics Executives and Management Board

Dr. Charles Baum65
Mirati Therapeutics President, Chief Executive Officer, Founder, Director, Head - Research and Development (since 2012)
Compensation 7.42 M
Mr. Benjamin Hickey48
Mirati Therapeutics Chief Commercial Officer
Compensation 6.93 M
Ms. Laurie Stelzer55
Mirati Therapeutics Chief Financial Officer
Compensation 5.8 M
Dr. James Christensen54
Mirati Therapeutics Chief Scientific Officer
Compensation 5.01 M
Dr. Alan Sandler66
Mirati Therapeutics Chief Medical Officer
Compensation 4.79 M
1
2
3

Mirati Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Verastem Stock
Verastem
SupplierCustomer0,810,840,340,810,820,33
BeiGene Stock
BeiGene
SupplierCustomer0,800,480,800,890,890,57
Zai Lab Stock
Zai Lab
SupplierCustomer0,610,670,470,840,81-
Sanofi Stock
Sanofi
SupplierCustomer0,570,73-0,54-0,81-0,86-0,86
ORIC Pharmaceuticals Stock
ORIC Pharmaceuticals
SupplierCustomer0,390,690,860,970,920,84
QIAGEN Stock
QIAGEN
SupplierCustomer0,250,630,620,880,710,41
Bristol-Myers Squibb Stock
Bristol-Myers Squibb
SupplierCustomer0,10-0,17-0,58-0,91-0,74-0,58
Pfizer Stock
Pfizer
SupplierCustomer-0,220,640,040,54-0,56-0,59
Novartis Stock
Novartis
SupplierCustomer-0,540,21-0,86-0,75-0,17-0,17
1

Most common questions regarding Mirati Therapeutics

What values and corporate philosophy does Mirati Therapeutics represent?

Mirati Therapeutics Inc represents values of innovation, collaboration, and patient-centricity. The company is dedicated to revolutionizing cancer treatment through the development of targeted therapies. With a strong focus on precision medicine, Mirati Therapeutics Inc aims to identify and address the specific genetic alterations driving cancer growth, providing potential solutions for patients with unmet medical needs. By fostering strategic partnerships and leveraging cutting-edge research, Mirati Therapeutics Inc aims to deliver breakthrough therapies for various forms of cancer. The company's corporate philosophy centers around scientific excellence, integrity, and a commitment to improving patient outcomes.

In which countries and regions is Mirati Therapeutics primarily present?

Mirati Therapeutics Inc primarily operates in the United States.

What significant milestones has the company Mirati Therapeutics achieved?

Some significant milestones achieved by Mirati Therapeutics Inc include the successful development of their precision oncology therapeutics, such as their lead candidate, adagrasib. Mirati Therapeutics has also achieved positive clinical trial results, demonstrating adagrasib's potential in treating certain types of advanced solid tumors with KRAS mutations. The company has made notable progress in expanding their pipeline, with the development of additional targeted therapies for cancer treatment. Mirati Therapeutics Inc has also entered into strategic collaborations and partnerships to further advance their research and development efforts. These achievements highlight the company's commitment to addressing unmet medical needs in the field of oncology.

What is the history and background of the company Mirati Therapeutics?

Mirati Therapeutics Inc is a renowned biotechnology company specializing in targeted oncology therapeutics. Established in 1995, Mirati has been dedicated to discovering and developing innovative treatments for patients with cancer. With a focus on precision medicine, the company is committed to addressing unmet medical needs by targeting specific genetic and biochemical drivers of cancer. Mirati Therapeutics has made significant advancements in the field of oncology, leveraging its expertise in precision oncology and targeted therapies. By combining cutting-edge research, strategic collaborations, and a patient-centric approach, Mirati Therapeutics continues to make strides in the fight against cancer.

Who are the main competitors of Mirati Therapeutics in the market?

The main competitors of Mirati Therapeutics Inc in the market include companies like Amgen, Inc., Bristol-Myers Squibb Company, and AstraZeneca plc.

In which industries is Mirati Therapeutics primarily active?

Mirati Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Mirati Therapeutics?

Mirati Therapeutics Inc is a leading biotechnology company with a business model focused on developing innovative targeted oncology therapeutics. With a strong emphasis on precision medicine, Mirati Therapeutics aims to develop and commercialize breakthrough therapies that target specific genetic mutations associated with various types of cancer. By leveraging their expertise in tumor biology and targeted therapies, Mirati Therapeutics aims to deliver transformative treatment options that address unmet medical needs. Through strategic collaborations and internal research and development efforts, Mirati Therapeutics strives to bring life-saving therapies to patients worldwide.

What is the P/E ratio of Mirati Therapeutics 2024?

The Mirati Therapeutics P/E ratio is -5.06.

What is the P/S ratio of Mirati Therapeutics 2024?

The Mirati Therapeutics P/S ratio is 18.08.

What is the AlleAktien quality score of Mirati Therapeutics?

The AlleAktien quality score for Mirati Therapeutics is 6/10.

What is the revenue of Mirati Therapeutics 2024?

The expected Mirati Therapeutics revenue is 182.56 M USD.

How high is the profit of Mirati Therapeutics 2024?

The expected Mirati Therapeutics profit is -652.86 M USD.

What is the business model of Mirati Therapeutics

Mirati Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of new targeted cancer therapies. The company aims to provide better treatment options for patients suffering from various types of cancer. Mirati Therapeutics is committed to developing drugs that target important signaling pathways in cancer cells and thus inhibit tumor growth.

What is the Mirati Therapeutics dividend?

Mirati Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Mirati Therapeutics pay dividends?

The dividend cannot currently be calculated for Mirati Therapeutics or the company does not pay out a dividend.

What is the Mirati Therapeutics ISIN?

The ISIN of Mirati Therapeutics is US60468T1051.

What is the Mirati Therapeutics WKN?

The WKN of Mirati Therapeutics is A1W1XV.

What is the Mirati Therapeutics ticker?

The ticker of Mirati Therapeutics is MRTX.

How much dividend does Mirati Therapeutics pay?

Over the past 12 months, Mirati Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mirati Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Mirati Therapeutics?

The current dividend yield of Mirati Therapeutics is .

When does Mirati Therapeutics pay dividends?

Mirati Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mirati Therapeutics?

Mirati Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Mirati Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mirati Therapeutics located?

Mirati Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mirati Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mirati Therapeutics from 9/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/18/2024.

When did Mirati Therapeutics pay the last dividend?

The last dividend was paid out on 9/18/2024.

What was the dividend of Mirati Therapeutics in the year 2023?

In the year 2023, Mirati Therapeutics distributed 0 USD as dividends.

In which currency does Mirati Therapeutics pay out the dividend?

The dividends of Mirati Therapeutics are distributed in USD.

All fundamentals about Mirati Therapeutics

Our stock analysis for Mirati Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mirati Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.